Well you knew this would happen eventually. Charging $800 a month for GI-protected naproxen (and ibuprofen)? HZNP overreached IMO. POZN thought AZN was charging too much and HZNP more than quadrupled its price. Better to have charged less and promoted more to reach a mass market.
Oh well, at least this won't affect HZNP's or POZN's revenues in 2014, and hopefully PA will be approved and launched by early 2015. By almost every conservative estimate, PA alone should more than justify POZN's current valuation unless it completely bombs, which seems unlikely.